Idiopathic giant-cell myocarditis - Natural history and treatment

Leslie T Jr. Cooper, Gerald J. Berry, Ralph Shabetai

Research output: Contribution to journalArticle

462 Citations (Scopus)

Abstract

Background: Idiopathic giant-cell myocarditis is a rare and frequently fatal disorder. We used a multi-center data base to define the natural history of giant-cell myocarditis and the effect of treatment. Methods: We identified 63 patients with idiopathic giant-cell myocarditis through journal announcements and direct mailings to cardiovascular centers worldwide. Results: The patients consisted of 33 men and 30 women with an average age of 42.6 years; 88 percent were white, 5 percent were black, 5 percent were Southeast Asian or Indian, and 2 percent were Middle Eastern. Most presented with congestive heart failure (47 patients, or 75 percent), ventricular arrhythmia (9 patients, or 14 percent), or heart block (3 patients, or 5 percent), although in some cases the initial symptoms resembled those of acute myocardial infarction (4 patients). Nineteen percent had associated autoimmune disorders. The rate of survival was worse than among 111 patients with lymphocytic myocarditis in the Myocarditis Treatment Trial (P<0.001); among our patients, the rate of death or cardiac transplantation was 89 percent, and median survival was only 5.5 months from the onset of symptoms. The 22 patients treated with corticosteroids and cyclosporine, azathioprine, or both therapies survived for an average of 12.3 months, as compared with an average of 3.0 months for the 30 patients who received no immunosuppressive therapy (P=0.001). Of the 34 patients who underwent heart transplantation, 9 (26 percent) had a giant-cell infiltrate in the transplanted heart and 1 died of recurrent giant-cell myocarditis. Conclusions: Giant-cell myocarditis is a disease of relatively young, predominantly healthy adults. Patients usually die of heart failure and ventricular arrhythmia unless cardiac transplantation is performed. Despite the possibility of fatal disease recurrence, transplantation is the treatment of choice for most patients.

Original languageEnglish (US)
Pages (from-to)1860-1866
Number of pages7
JournalNew England Journal of Medicine
Volume336
Issue number26
DOIs
StatePublished - Jun 26 1997

Fingerprint

Myocarditis
Giant Cells
Natural History
Therapeutics
Heart Transplantation
Cardiac Arrhythmias
Heart Failure
Heart Block
Azathioprine
Immunosuppressive Agents
Cyclosporine
Adrenal Cortex Hormones
Survival Rate
Transplantation
Myocardial Infarction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Idiopathic giant-cell myocarditis - Natural history and treatment. / Cooper, Leslie T Jr.; Berry, Gerald J.; Shabetai, Ralph.

In: New England Journal of Medicine, Vol. 336, No. 26, 26.06.1997, p. 1860-1866.

Research output: Contribution to journalArticle

Cooper, Leslie T Jr. ; Berry, Gerald J. ; Shabetai, Ralph. / Idiopathic giant-cell myocarditis - Natural history and treatment. In: New England Journal of Medicine. 1997 ; Vol. 336, No. 26. pp. 1860-1866.
@article{46fe8dcb44864e8897fb24f05311a988,
title = "Idiopathic giant-cell myocarditis - Natural history and treatment",
abstract = "Background: Idiopathic giant-cell myocarditis is a rare and frequently fatal disorder. We used a multi-center data base to define the natural history of giant-cell myocarditis and the effect of treatment. Methods: We identified 63 patients with idiopathic giant-cell myocarditis through journal announcements and direct mailings to cardiovascular centers worldwide. Results: The patients consisted of 33 men and 30 women with an average age of 42.6 years; 88 percent were white, 5 percent were black, 5 percent were Southeast Asian or Indian, and 2 percent were Middle Eastern. Most presented with congestive heart failure (47 patients, or 75 percent), ventricular arrhythmia (9 patients, or 14 percent), or heart block (3 patients, or 5 percent), although in some cases the initial symptoms resembled those of acute myocardial infarction (4 patients). Nineteen percent had associated autoimmune disorders. The rate of survival was worse than among 111 patients with lymphocytic myocarditis in the Myocarditis Treatment Trial (P<0.001); among our patients, the rate of death or cardiac transplantation was 89 percent, and median survival was only 5.5 months from the onset of symptoms. The 22 patients treated with corticosteroids and cyclosporine, azathioprine, or both therapies survived for an average of 12.3 months, as compared with an average of 3.0 months for the 30 patients who received no immunosuppressive therapy (P=0.001). Of the 34 patients who underwent heart transplantation, 9 (26 percent) had a giant-cell infiltrate in the transplanted heart and 1 died of recurrent giant-cell myocarditis. Conclusions: Giant-cell myocarditis is a disease of relatively young, predominantly healthy adults. Patients usually die of heart failure and ventricular arrhythmia unless cardiac transplantation is performed. Despite the possibility of fatal disease recurrence, transplantation is the treatment of choice for most patients.",
author = "Cooper, {Leslie T Jr.} and Berry, {Gerald J.} and Ralph Shabetai",
year = "1997",
month = "6",
day = "26",
doi = "10.1056/NEJM199706263362603",
language = "English (US)",
volume = "336",
pages = "1860--1866",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "26",

}

TY - JOUR

T1 - Idiopathic giant-cell myocarditis - Natural history and treatment

AU - Cooper, Leslie T Jr.

AU - Berry, Gerald J.

AU - Shabetai, Ralph

PY - 1997/6/26

Y1 - 1997/6/26

N2 - Background: Idiopathic giant-cell myocarditis is a rare and frequently fatal disorder. We used a multi-center data base to define the natural history of giant-cell myocarditis and the effect of treatment. Methods: We identified 63 patients with idiopathic giant-cell myocarditis through journal announcements and direct mailings to cardiovascular centers worldwide. Results: The patients consisted of 33 men and 30 women with an average age of 42.6 years; 88 percent were white, 5 percent were black, 5 percent were Southeast Asian or Indian, and 2 percent were Middle Eastern. Most presented with congestive heart failure (47 patients, or 75 percent), ventricular arrhythmia (9 patients, or 14 percent), or heart block (3 patients, or 5 percent), although in some cases the initial symptoms resembled those of acute myocardial infarction (4 patients). Nineteen percent had associated autoimmune disorders. The rate of survival was worse than among 111 patients with lymphocytic myocarditis in the Myocarditis Treatment Trial (P<0.001); among our patients, the rate of death or cardiac transplantation was 89 percent, and median survival was only 5.5 months from the onset of symptoms. The 22 patients treated with corticosteroids and cyclosporine, azathioprine, or both therapies survived for an average of 12.3 months, as compared with an average of 3.0 months for the 30 patients who received no immunosuppressive therapy (P=0.001). Of the 34 patients who underwent heart transplantation, 9 (26 percent) had a giant-cell infiltrate in the transplanted heart and 1 died of recurrent giant-cell myocarditis. Conclusions: Giant-cell myocarditis is a disease of relatively young, predominantly healthy adults. Patients usually die of heart failure and ventricular arrhythmia unless cardiac transplantation is performed. Despite the possibility of fatal disease recurrence, transplantation is the treatment of choice for most patients.

AB - Background: Idiopathic giant-cell myocarditis is a rare and frequently fatal disorder. We used a multi-center data base to define the natural history of giant-cell myocarditis and the effect of treatment. Methods: We identified 63 patients with idiopathic giant-cell myocarditis through journal announcements and direct mailings to cardiovascular centers worldwide. Results: The patients consisted of 33 men and 30 women with an average age of 42.6 years; 88 percent were white, 5 percent were black, 5 percent were Southeast Asian or Indian, and 2 percent were Middle Eastern. Most presented with congestive heart failure (47 patients, or 75 percent), ventricular arrhythmia (9 patients, or 14 percent), or heart block (3 patients, or 5 percent), although in some cases the initial symptoms resembled those of acute myocardial infarction (4 patients). Nineteen percent had associated autoimmune disorders. The rate of survival was worse than among 111 patients with lymphocytic myocarditis in the Myocarditis Treatment Trial (P<0.001); among our patients, the rate of death or cardiac transplantation was 89 percent, and median survival was only 5.5 months from the onset of symptoms. The 22 patients treated with corticosteroids and cyclosporine, azathioprine, or both therapies survived for an average of 12.3 months, as compared with an average of 3.0 months for the 30 patients who received no immunosuppressive therapy (P=0.001). Of the 34 patients who underwent heart transplantation, 9 (26 percent) had a giant-cell infiltrate in the transplanted heart and 1 died of recurrent giant-cell myocarditis. Conclusions: Giant-cell myocarditis is a disease of relatively young, predominantly healthy adults. Patients usually die of heart failure and ventricular arrhythmia unless cardiac transplantation is performed. Despite the possibility of fatal disease recurrence, transplantation is the treatment of choice for most patients.

UR - http://www.scopus.com/inward/record.url?scp=1842410169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842410169&partnerID=8YFLogxK

U2 - 10.1056/NEJM199706263362603

DO - 10.1056/NEJM199706263362603

M3 - Article

C2 - 9197214

AN - SCOPUS:1842410169

VL - 336

SP - 1860

EP - 1866

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 26

ER -